|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology显示文摘Next-generation sequencing(NGS) technology is capable of sequencing millions or billions of DNA molecules simultaneously.Therefore, it represents a promising tool for the analysis of molecular targets for the initial diagnosis of disease, monitoring of disease progression, and identifying the mechanism of drug resistance. On behalf of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology(CSCO) and the China Actionable Genome Consortium(CAGC), the present expert group hereby proposes advisory guidelines on clinical applications of NGS technology for the analysis of cancer driver genes for precision cancer therapy. This group comprises an assembly of laboratory cancer geneticists, clinical oncologists, bioinformaticians,pathologists, and other professionals. After multiple rounds of discussions and revisions, the expert group has reached a preliminary consensus on the need of NGS in clinical diagnosis, its regulation, and compliance standards in clinical sample collection. Moreover, it has prepared NGS criteria, the sequencing standard operation procedure(SOP), data analysis, report, and NGS platform certification and validation. | Xuchao Zhang Zhiyong Liang Shengyue Wang Shun Lu Yong Song Ying Cheng Jianming Ying Weiping Liu Yingyong Hou Yangqiu Li Yi Liu Jun Hou Xiufeng Liu Jianyong Shao Yanhong Tai Zheng Wang Li Fu Hui Li Xiaojun Zhou Hua Bai Mengzhao Wang You Lu Jinji Yang Wenzhao Zhong Qing Zhou Xuening Yang Jie Wang Cheng Huang Xiaoqing Liu Xiaoyan Zhou Shirong Zhang Hongxia Tian Yu Chen Ruibao Ren Ning Liao Chunyan Wu Zhongzheng Zhu Hongming Pan Yanhong Gu Liwei Wang Yunpeng Liu Suzhan Zhang Tianshu Liu Gong Chen Zhimin Shao Binghe Xu Qingyuan Zhang Ruihua Xu Lin Shen Yilong Wu | 2019 | Cancer Biology & Medicine2019，16，1： | 14 |
| 2 | Chinese expert consensus on conversion therapy for hepatocellular carcinoma(2021 edition)显示文摘Recent advances in systemic and locoregional treatments for patients with unresectable or advanced hepatocellular carcinoma(HCC)have resulted in improved response rates.This has provided an opportunity for selected patients with initially unresectable HCC to achieve adequate tumor downstaging to undergo surgical resection,a‘conversion therapy’strategy.However,conversion therapy is a new approach to the treatment of HCC and its practice and treatment protocols are still being developed.Review the evidence for conversion therapy in HCC and develop consensus statements to guide clinical practice.Evidence review:Many research centers in China have accumulated significant experience implementing HCC conversion therapy.Preliminary findings and data have shown that conversion therapy represents an important strategy to maximize the survival of selected patients with intermediate stage to advanced HCC;however,there are still many urgent clinical and scientific challenges for this therapeutic strategy and its related fields.In order to summarize and learn from past experience and review current challenges,the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma(2021 Edition)was developed based on a review of preliminary experience and clinical data from Chinese and non-Chinese studies in this field and combined with recommendations for clinical practice.Sixteen consensus statements on the implementation of conversion therapy for HCC were developed.The statements generated in this review are based on a review of clinical evidence and real clinical experience and will help guide future progress in conversion therapy for patients with HCC. | Hui-Chuan Sun Jian Zhou Zheng Wang Xiufeng Liu Qing Xie Weidong Jia Ming Zhao Xinyu Bi Gong Li Xueli Bai Yuan Ji Li Xu Xiao-Dong Zhu Dousheng Bai Yajin Chen Yongjun Chen Chaoliu Dai Rongping Guo Wenzhi Guo Chunyi Hao Tao Huang Zhiyong Huang Deyu Li Gang Li Tao Li Xiangcheng Li Guangming Li Xiao Liang Jingfeng Liu Fubao Liu Shichun Lu Zheng Lu Weifu Lv Yilei Mao Guoliang Shao Yinghong Shi Tianqiang Song Guang Tan Yunqiang Tang Kaishan Tao Chidan Wan Guangyi Wang Lu Wang Shunxiang Wang Tianfu Wen Baocai Xing Bangde Xiang Sheng Yan Dinghua Yang Guowen Yin Tao Yin Zhenyu Yin Zhengping Yu Bixiang Zhang Jialin Zhang Shuijun Zhang Ti Zhang Yamin Zhang Yubao Zhang Aibin Zhang Haitao Zhao Ledu Zhou Wu Zhang Zhenyu Zhu Shukui Qin Feng Shen Xiujun Cai Gaojun Teng Jianqiang Cai Minshan Chen Qiang Li Lianxin Liu Weilin Wang Tingbo Liang Jiahong Dong Xiaoping Chen Xuehao Wang Shusen Zheng Jia Fan 无 | 2022 | Hepatobiliary Surgery and Nutrition2022，11，2： | 4 |
| 3 | Manipulating fluid with vibrating 3D-printed paddles for applications in micropump显示文摘This paper presents a novel working mechanism of a micropump using micropaddles(MPs)to actively manipulate fluid based on 3 D printing technology.The novel working principle is systematically discussed using analysis,computation and experiment methods.A theoretical model is established to research the working mechanism and crucial parameters for driving ability,such as MPs shape,size,vibration amplitude and frequency.Two different 3 D printing techniques that simplify the multi-step process into only one step are introduced to manufacture the prototype pump for investigating the principle experimentally.A testing system is designed to evaluate the flow rate of pumps with eight different vibrating paddles.A maximum flux of 127.9 mL/min is obtained at an applied voltage of 9 V.These experiments show that the active-type mechanical pump could not only freely control flow direction but also change flux by adopting different shapes or distribution ways.The advantage of the novel micropump is the application of the MP structure into the micropump system to actively manipulate fluid with flexibility and high driving ability at fairly low power. | Zhiyong Tang Xiufeng Shao Jianze Huang Jinyuan Yao Guifu Ding | 2019 | Nanotechnology and Precision Engineering2019，2，3： | 0 |
| 4 | Effect Trials on Abamectin + Chlorpyrifos 8% GR for Controlling Turf Grubs显示文摘To screen high-efficiency,low-toxicity,and safe pesticides for controlling soil pests,experimental investigations of Abamectin + Chlorpyrifos 8% GR for controlling turf grubs were implemented according to Field Pharmacodynamic Test Standards of the Ministry of Agriculture. The results showed that as the active ingredient of Abamectin + Chlorpyrifos 8% GR is 1 625- 1 950 g / hm2,the control efficiency of turf grubs is 81. 43%-90. 46% 3-10 days after pesticide application,the readily availability and persistent effect achieve the ideal level,and it is safe for turf. | Sun Shujun You Xiufeng Shao Mei | 2015 | Plant Diseases and Pests2015，6，1： | 0 |
| 5 | An experimental research into endostatin microbubble combined with focused ultrasound for anti-tumor angiogenesis in colon cancer显示文摘Objective:to evaluate the therapeutic effect of targeted endostatin-loaded microbubbles,combined with improved,focused,directional ultrasound radiation for inhibition of subcutaneous translocation in situ colon tumor angiogenesis in colon cancer.Methods:65 BALB/c nude mice with subcutaneous translocation in situ colon tumors were randomly divided into five groups.Group A was the control group,without any treatments.In Group B,the mouse was treated with ultrasonic radiation.In Group C,the mouse was treated with ultrasonic radiation combined with empty SonoVue microbubbles.In Group D,the mouse was treated with ultrasonic radiation combined with empty Targestar-SA microbubbles.In Group E,the mouse was treated with ultrasonic radiation combined with endostatin microbubbles.The tumor size was measured before and 1,14,and 28 days after irradiation.The peak intensity(PI),regional blood volume(RBV)and regional blood flow(RBF)were recorded using contrast-enhanced ultrasound.The tumor tissue was removed for pathological examination;the tumor necrosis area and microvascular density(MVD)were evaluated by immunohistochemistry.Results:Tumors in Groups C,D and E were significantly smaller than in Groups A and B at 28 days after irradiation,with Group E the smallest.PI,RBF and RBV of Groups C,D,and E were significantly decreased 28 days after radiation with Group E the lowest,and significantly lower than Groups A and B(all P<0.05).The tumor tissue necrosis area of Group E was clearly greater while MVD was obviously lower than the other groups(all P<0.01)at 28 days after treatment.Conclusion:The targeted endostatin microbubbles,combined with focused,directional ultrasound radiation can damage tumor microvasculature of subcutaneous colon translocation in situ colon cancer,as well as inhibit the tumor angiogenesis. | Xiufeng Zhang Guangen Yang Ying Zhang Pintong Huang Jianming Qiu Yu Sun Zhong Shen Xiujun Liao Hongsheng Xia Shuxian Shao Dong Wang | 2014 | Gastroenterology Report2014，2，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员